Seoul National University Hospital Research Team
Validation of a Noninvasive Assessment Strategy Combining Donor-Specific Antibodies and Cell-Free DNA
Confirmed a 97.8% Negative Predictive Value for the Low-Risk Group

A team of Korean researchers has demonstrated a blood test-based risk assessment strategy that can reduce the need for invasive biopsies performed to detect rejection after kidney transplantation.


From the left, Sangil Min and Ara Jo, professors of Vascular Surgery at Seoul National University Hospital. Seoul National University Hospital

From the left, Sangil Min and Ara Jo, professors of Vascular Surgery at Seoul National University Hospital. Seoul National University Hospital

View original image

On June 4, Seoul National University Hospital announced that the research team led by Professors Ara Cho and Sangil Min from the Department of Vascular Transplant Surgery, in collaboration with Professor Joo Han Lee of Severance Hospital and Professor Cheol Woong Jung of Korea University Anam Hospital, has confirmed the usefulness of a noninvasive assessment method for predicting subclinical rejection in kidney transplant recipients. The results of the study were published in the online edition of the international journal 'International Journal of Surgery.'


De novo donor-specific antibodies (dnDSA), which newly develop after kidney transplantation, are a representative immunological risk signal indicating rejection and decline in graft function. However, among patients in whom these antibodies are detected, the actual rate of confirmed rejection through biopsy is only 30–40 percent. As a result, a significant number of patients have to undergo biopsies, which carry risks of bleeding, pain, and hospitalization.


The research team focused on donor-derived cell-free DNA (dd-cfDNA), which has recently attracted attention as a noninvasive biomarker. Cell-free DNA refers to fragments of DNA released into the bloodstream when immunological injury or inflammation occurs in the transplanted kidney.


The researchers prospectively analyzed blood cell-free DNA levels and biopsy results from 123 patients with stable graft function at three transplant centers in Korea. The participants included 77 patients who tested positive for donor-specific antibodies and 46 who tested negative.


The analysis found that the median level of cell-free DNA in the donor-specific antibody-positive group was 1.2 percent, higher than the 0.3 percent observed in the negative group. Additionally, as microvascular inflammation in the kidney became more severe, cell-free DNA levels tended to increase. According to the Banff criteria, the international standard for biopsy diagnosis, the median cell-free DNA level was 0.54 percent in patients with an inflammation score of 0–1, but increased to 1.6 percent or higher in those with a score of 2 or more.


The performance of rejection prediction also improved. When relying solely on donor-specific antibodies, the diagnostic performance (AUC) was 0.74; however, when the cell-free DNA test was added, it increased to 0.81.


In particular, when patients with cell-free DNA levels below 1.0 percent were classified as low risk, the negative predictive value, indicating the probability that these patients truly did not have rejection, reached 97.8 percent. The research team expects that this will enable more accurate identification of patients who do not require a biopsy.



Sangil Min, Professor of Vascular Transplant Surgery at Seoul National University Hospital, stated, "Even when donor-specific antibodies are detected, performing biopsies on all patients equally can be burdensome. By combining noninvasive biomarkers, we have confirmed that it is possible to more precisely identify patients at truly high risk for rejection." He added, "Appropriate use of cell-free DNA in the clinical decision-making process could evolve into a personalized monitoring strategy that detects graft injury early while reducing patient burden."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing